Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.84 |
| ▸ | MET | P08581 | 10/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.84 |
| ▸ | KDR | P35968 | 4/20 | 0.84 |
| ▸ | FLT1 | P17948 | 3/20 | 0.84 |
| ▸ | MERTK | Q12866 | 3/20 | 0.84 |
| ▸ | FLT3 | P36888 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 1/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.84 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.84 |
| ▸ | LCK | P06239 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | LYN | P07948 | 1/20 | 0.84 |
| ▸ | RET | P07949 | 1/20 | 0.84 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.84 |
| ▸ | HCK | P08631 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872120 | 0.96 | AXL (0.90) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL30918289 | 0.96 | AXL (0.90) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL19766271 | 0.94 | AXL (0.75) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL19652540 | 0.93 | MET (0.73) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL371951 | 0.92 | AURKB (0.87) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL24444625 | 0.92 | AXL (0.71) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL29258975 | 0.92 | AXL (0.81) | AXLMETAURKBKDRFLT1 | |
| SCHEMBL19766275 | 0.91 | MET (0.71) | AXLMETAURKBKDRFLT1 | |
| Cabozantinib SCHEMBL360795 | 0.91 | AXL (1.00) | AXLMETAURKBKDRFLT1 | |
| Cabozantinib SCHEMBL29728791 | 0.91 | AXL (1.00) | AXLMETAURKBKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914622-B1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3134084-B1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS INC (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AXL 859/4885MET 1050/4885AURKB 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.